Options
SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class : correspondence
Schernthaner, Guntram | Department of Medicine I, Rudolfstitung Hospital, Vienna, Austria |
Drexel, Heinz | VIVIT-Institute, Academic Teaching Hospital Feldkirch, Feldkirch, Austria |
Moshkovich, Evgeny | Unit of Endocrinology and Metabolism, Sapir Medical Center, Kfar-Saba, Israel |
Martinka, Emil | National Institute of Endocrinology and Diabetology, Lubochna, Slovakia |
Czupryniak, Leszek | Department of Diabetology and Internal Medicine, Warsaw Medical University, Warsaw, Poland |
Várkonyi, Tamás | 1st Dept of Internal Medicine, University of Szeged, Szeged, Hungary |
Janež, Andrej | Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre, Ljubljana, Slovenia |
Ducena, Kristine | Division of Endocrinology, Faculty of Internal Medicine, University of Latvia, Riga, Latvia |
Lalić, Katarina | Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Beograd, Serbia |
Tankova, Tsvetalina | Clinical Centre of Endocrinology, Medical University - Sofia, Sofia, Bulgaria |
Prázný, Martin | Diabetes Centre, Charles University and General Faculty Hospital, Prague, Czech Republic |
Smirčić Duvnjak, Lea | School of Medicine, University of Zagreb, Vuk Vrhovac University Clinic-UH Merkur, Zagreb, Croatia |
Sukhareva, Olga | Endocrinology Research Centre, Moscow, Russian Federation |
Sourij, Harald | Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria |
| Date Issued |
|---|
2019-06-17 |
OA
BACKGROUND: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. EXPERT OPINION: To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence. CONCLUSION: CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.